- Home
- HG vs ADPT Comparison
HG vs ADPT Comparison
Compare HG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | ADPT |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HG | ADPT |
|---|---|---|
| Price | $29.07 | $13.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $31.25 | $17.78 |
| AVG Volume (30 Days) | 566.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 6.99% | N/A |
| EPS Growth | 51.23 | ★ 63.89 |
| EPS | ★ 5.55 | N/A |
| Revenue | ★ $2,905,524,000.00 | $276,976,000.00 |
| Revenue This Year | $1.63 | $3.98 |
| Revenue Next Year | $12.67 | $22.72 |
| P/E Ratio | $5.15 | ★ N/A |
| Revenue Growth | 24.70 | ★ 54.77 |
| 52 Week Low | $16.80 | $6.68 |
| 52 Week High | $32.21 | $20.76 |
Technical Indicators
Market Signals| Indicator | HG | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 30.42 |
| Support Level | $28.83 | $12.32 |
| Resistance Level | $31.94 | $13.45 |
| Average True Range (ATR) | 0.84 | 0.82 |
| MACD | -0.37 | -0.29 |
| Stochastic Oscillator | 37.72 | 20.71 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).